NUF2 Activated by YY1 Promotes Prostate Cancer Malignancy via P38/MAPK Signaling Axis and Serves As a Therapeutic Target

Researchers demonstrated that NUF2 was significantly overexpressed in prostate cancer, with its elevated levels correlating with poor patient survival outcomes.